The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Tiago Biachi, MD, PhD, emphasizes that biosimilars are vital for reducing financial toxicity and ensuring equitable, affordable access to advanced treatments in gastrointestinal (GI) cancer care, ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

Number 4: The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...